Theravance Biopharma, Inc.
TBPH
$16.48
-$0.04-0.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -61.43% | 129.57% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -61.43% | 129.57% | |||
| Cost of Revenue | -20.80% | -9.27% | |||
| Gross Profit | -69.19% | 224.39% | |||
| SG&A Expenses | -4.32% | 1.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.01% | -2.14% | |||
| Operating Income | -129.23% | 410.01% | |||
| Income Before Tax | -108.85% | 2,629.18% | |||
| Income Tax Expenses | -112.76% | 285.18% | |||
| Earnings from Continuing Operations | -108.08% | 1,588.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -108.08% | 1,588.08% | |||
| EBIT | -129.23% | 410.01% | |||
| EBITDA | -126.80% | 437.36% | |||
| EPS Basic | -108.02% | 1,575.56% | |||
| Normalized Basic EPS | 94.59% | -1,692.16% | |||
| EPS Diluted | -108.33% | 1,549.14% | |||
| Normalized Diluted EPS | 94.36% | -1,662.64% | |||
| Average Basic Shares Outstanding | 0.81% | 0.69% | |||
| Average Diluted Shares Outstanding | -3.34% | 2.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||